scispace - formally typeset
Search or ask a question
Author

Sviatlana Zhyzhneuskaya

Bio: Sviatlana Zhyzhneuskaya is an academic researcher from Newcastle University. The author has contributed to research in topics: Weight loss & Type 2 diabetes. The author has an hindex of 8, co-authored 15 publications receiving 1272 citations.

Papers
More filters
Journal ArticleDOI
TL;DR: This study demonstrates that β cell ability to recover long-term function persists after diagnosis, changing the previous paradigm of irreversible loss of β cell function in type 2 diabetes.

236 citations

Journal ArticleDOI
TL;DR: Timely relationships between VLDL1-triglyceride production, hepatic palmitic acid flux, intra-pancreatic fat, and β-cell function are observed to drive development and reversal of type 2 diabetes.

87 citations

Journal ArticleDOI
TL;DR: The Diabetes Remission Clinical Trial (DiRECT) was designed to determine whether a structured, intensive, weight management programme, delivered in a routine Primary Care setting, is a viable treatment for achieving durable normoglycaemia.
Abstract: Despite improving evidence-based practice following clinical guidelines to optimise drug therapy, Type 2 diabetes (T2DM) still exerts a devastating toll from vascular complications and premature death. Biochemical remission of T2DM has been demonstrated with weight loss around 15kg following bariatric surgery and in several small studies of non-surgical energy-restriction treatments. The non-surgical Counterweight-Plus programme, running in Primary Care where obesity and T2DM are routinely managed, produces >15 kg weight loss in 33 % of all enrolled patients. The Diabetes UK-funded Counterpoint study suggested that this should be sufficient to reverse T2DM by removing ectopic fat in liver and pancreas, restoring first-phase insulin secretion. The Diabetes Remission Clinical Trial (DiRECT) was designed to determine whether a structured, intensive, weight management programme, delivered in a routine Primary Care setting, is a viable treatment for achieving durable normoglycaemia. Other aims are to understand the mechanistic basis of remission and to identify psychological predictors of response. Cluster-randomised design with GP practice as the unit of randomisation: 280 participants from around 30 practices in Scotland and England will be allocated either to continue usual guideline-based care or to add the Counterweight-Plus weight management programme, which includes primary care nurse or dietitian delivery of 12-20weeks low calorie diet replacement, food reintroduction, and long-term weight loss maintenance. Main inclusion criteria: men and women aged 20-65years, all ethnicities, T2DM 0-6years duration, BMI 27-45 kg/m2. Tyneside participants will undergo Magnetic Resonance (MR) studies of pancreatic and hepatic fat, and metabolic studies to determine mechanisms underlying T2DM remission. Co-primary endpoints: weight reduction ≥ 15 kg and HbA1c <48 mmol/mol at one year. Further follow-up at 2 years. This study will establish whether a structured weight management programme, delivered in Primary Care by practice nurses or dietitians, is a viable treatment to achieve T2DM remission. Results, available from 2018 onwards, will inform future service strategy. Current Controlled Trials ISRCTN03267836 . Date of Registration 20/12/2013

76 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: A panel to update the prior position statements on the management of type 2 diabetes in adults includes additional focus on lifestyle management and diabetes self-management education and support and efforts targeting weight loss.
Abstract: The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium-glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min-1 [1.73 m]-2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.

2,592 citations

Journal ArticleDOI
Frank L.J. Visseren, François Mach, Yvo M. Smulders, David Carballo, Konstantinos C. Koskinas, Maria Bäck, Athanase Benetos, Alessandro Biffi, José-Manuel Boavida1, Davide Capodanno, Bernard Cosyns, Carolyn Crawford, Constantinos H. Davos, Ileana Desormais, Emanuele Di Angelantonio, Oscar H. Franco, Sigrun Halvorsen, FD Richard Hobbs, Monika Hollander, Ewa A. Jankowska, Matthias Michal, Simona Sacco, Naveed Sattar, Lale Tokgozoglu, Serena Tonstad, Konstantinos P Tsioufis2, Ineke van Dis, Isabelle C. Van Gelder, Christoph Wanner3, Bryan Williams, Guy De Backer, Vera Regitz-Zagrosek, Anne Hege Aamodt, Magdy Abdelhamid, Victor Aboyans, Christian Albus, Riccardo Asteggiano, Magnus Bäck, Michael A. Borger, Carlos Brotons, Jelena Čelutkienė, Renata Cifkova, Maja Čikeš, Francesco Cosentino, Nikolaos Dagres, Tine De Backer, Dirk De Bacquer, Victoria Delgado, Hester Den Ruijter, Paul Dendale, Heinz Drexel, Volkmar Falk, Laurent Fauchier, Brian A. Ference, Jean Ferrières, Marc Ferrini4, Miles Fisher4, Danilo Fliser3, Zlatko Fras, Dan Gaita, Simona Giampaoli, Stephan Gielen, Ian D. Graham, Catriona Jennings, Torben Jørgensen, Alexandra Kautzky-Willer, Maryam Kavousi, Wolfgang Koenig, Aleksandra Konradi, Dipak Kotecha, Ulf Landmesser, Madalena Lettino, Basil S. Lewis, Aleš Linhart, Maja-Lisa Løchen1, Konstantinos Makrilakis1, Giuseppe Mancia2, Pedro Marques-Vidal, John W. McEvoy, Paul McGreavy, Béla Merkely, Lis Neubeck, Jens Cosedis Nielsen, Joep Perk, Steffen E. Petersen, Anna Sonia Petronio, Massimo F Piepoli, Nana Pogosova, Eva Prescott, Kausik K. Ray, Zeljko Reiner, Dimitrios J. Richter, Lars Rydén, Evgeny Shlyakhto, Marta Sitges, Miguel Sousa-Uva, Isabella Sudano, Monica Tiberi, Rhian M. Touyz, Andrea Ungar, W. M. Monique Verschuren, Olov Wiklund, David A. Wood, José Luis Zamorano, Carolyn A Crawford, Oscar H Franco Duran 

1,650 citations

01 Jan 1980

1,523 citations

Journal ArticleDOI
TL;DR: A panel to update the prior position statements on the management of type 2 diabetes in adults includes additional focus on lifestyle management and diabetes self-management education and support and efforts targeting weight loss.
Abstract: The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium–glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.

1,192 citations